Cambridge Consultants To Unveil New Licensing Program For Dry Powder Inhaler "Gen-X" Development Tools At The Respiratory Drug Delivery Conference
Main Category: Pharma Industry / Biotech IndustryAlso Included In: Regulatory Affairs / Drug Approvals
Article Date: 13 May 2008 - 2:00 PDT
Accelerating the creation of new inhalable drug delivery devices, Cambridge Consultants (http://www.cambridgeconsultants.com) is announcing the licensing of a range of technology development tools at the Respiratory Drug Delivery Conference in Scottsdale, Ariz. The company's Gen-X series of technologies, from de-agglomeration for fine particle doses (FPD) to drug storage chamber piercing and evacuation techniques, draw on the scientific and engineering expertise of being involved in the development of more than 16 respiratory delivery devices over the past 15 years.
"In an industry where the time-to-market for inhalable dry powder drug delivery devices is often seven to 10 years, fast-tracking development with our proven Gen-X development platform can significantly reduce this timescale and the overall development risk." said Marek Myszko, business development manager, Drug Delivery at Cambridge Consultants. "A 40- to 60-percent reduction in time to market creates a significant competitive value and faster revenue to a company's bottom line in a market where generating market presence is particularly important."
The group of core Gen-X technologies being licensed by Cambridge Consultants include the technology to accurately pierce a foil blister, evacuate the blister in a repeatable manner, and drug de-agglomerate technologies to provide tailored device performance. These, coupled with Cambridge Consultants' proven expertise in the development of solutions to technical challenges such as dose indexing and human factors, provide a quick development path for new DPIs.
Cambridge Consultants is highlighting its Gen-X DPI technologies at the Respiratory Drug Delivery 2008 conference in Scottsdale, Ariz., from May 11-15.
About Cambridge Consultants
Cambridge Consultants develops breakthrough products, creates and licenses intellectual property, and provides business consultancy in technology critical issues for clients worldwide. For nearly 50 years, the company has enabled its clients to turn business opportunities into commercial successes, whether launching first-to-market products, entering new markets or expanding existing markets through the introduction of new technologies. With a team of over 250 engineers, designers, scientists and consultants, in offices in Cambridge (UK) and Boston (USA), Cambridge Consultants offers solutions across a diverse range of industries including medical technology, industrial and consumer products, automotive, transport, energy and wireless communications. For more information visit: http://www.cambridgeconsultants.com.
Cambridge Consultants is part of the Altran group of companies. Altran Technologie, which is listed on the Paris Stock Exchange (FR:003463), employs more than 17,000 consultants in 20 countries around the world. In 2006 the group generated a turnover of €1,495.6 million.
http://www.altran.com
|
Please rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add to:
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
| Back to top | Back to front page | List of All Medical Articles |
| Privacy Policy | Terms and Conditions | © 2008 MediLexicon International Ltd |




